Bradley Rosen
Los Angeles physician, originally trained as a retina specialist, who runs a longevity-medicine practice built around rapamycin and metformin, and senior author of a cautious review of the human evidence for off-label rapamycin in healthy adults
Physician, MTOR MD longevity practice, Los Angeles · retina fellowships, Lions Eye Institute (Perth) and Royal Victorian Eye and Ear Hospital (Melbourne) · ophthalmology residency, Jules Stein Eye Institute, UCLA · MD, University of Florida
MTOR MD (Los Angeles, California, USA) ↗
Rapamycin extends lifespan in laboratory animals, and some doctors now prescribe it in low doses to healthy people hoping to slow ageing. HAN2025, a 2025 review in Aging with Bradley Rosen as last author, asks what the human evidence actually shows. The authors gathered the clinical studies of rapamycin and related mTOR inhibitors in healthy adults and re-analysed one cohort with PhenoAge, a biological-age score calculated from blood tests. Their conclusion is careful: the animal data are strong, but human studies have not yet shown that rapamycin slows ageing in healthy people. The review is useful because it holds human data to a strict standard.
Rosen came to this field from eye medicine. A podcast biography says he studied mathematics and statistics, earned an MD at the University of Florida, trained in ophthalmology at the Jules Stein Eye Institute at UCLA, and did retina fellowships at the Lions Eye Institute in Western Australia and the Royal Victorian Eye and Ear Hospital in Melbourne. PubMed has a 1999 case report from the Lions Eye Institute with him as first author, on eye inflammation in cat scratch disease. According to the same biography, he turned to the biology of ageing in 2013.
He now runs MTOR MD, a longevity-medicine practice in Los Angeles. Its website describes mTOR inhibition with rapamycin and AMPK targeting with metformin as its core treatments, alongside work on diet, exercise, sleep and metabolic health. On the review PubMed lists his affiliation as an mTOR medicine practitioner in Los Angeles.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2025 | R | What is the clinical evidence to support off-label rapamycin therapy in healthy adults? HAN2025 Last author: a review concluding that human evidence does not yet show that low-dose rapamycin slows ageing in healthy adults, with a PhenoAge re-analysis of one cohort. |
Co-authors in the Atlas 1
People with a profile here who share at least one study with Bradley Rosen.
ShowHide
- Jacob M Hands Researcher in integrative medicine and nutrition science, trained at George Washington University, who wrote a cautious review of whether off-label rapamycin is justified for healthy adults
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.